Home › Companies › Teva Pharmaceutical Industries Limited › 2025-2026
Compiled from SEC Form N-PX filings and Teva Pharmaceutical Industries Limited’s Form 8-K, filed 2026-05-28 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Teva Pharmaceutical Industries Limited in the interactive database Compare manager voting policies
These tallies are Teva Pharmaceutical Industries Limited’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Dr. Sol J. Barer | 627,816,662 | 245,921,571 | 530,682 | -- | 50,661,570 | Majority: yes |
| (2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows: | 795,976,042 | 77,082,847 | 1,170,026 | -- | 50,661,570 | Majority: yes |
| (3) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd. | 880,542,242 | 36,085,507 | 525,382 | -- | 0 | Majority: yes |
Source: Teva Pharmaceutical Industries Limited, Form 8-K, filed with the SEC on 2026-05-28 — read the filing on EDGAR.
Each item below shows how the 623 asset managers that disclosed a Teva Pharmaceutical Industries Limited vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Teva Pharmaceutical Industries Limited’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-05-28.
Combines 24 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Teva Pharmaceutical Industries Limited’s own tally for this item (“(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:”): 795,976,042 for, 77,082,847 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,164,426,972 outstanding shares: 68% for, 7% against (75% of the company cast a for/against vote).
The 615 asset managers below cast 94% of the shares they voted on this item FOR (626,636,049 for, 41,777,249 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 70,259,885 | 0 | 0 | 0 | For |
| Fidelity | 64,673,495 | 0 | 0 | 0 | For |
| Migdal Insurance & Financial Holdings Ltd. | 60,694,120 | 0 | 0 | 0 | For |
| Phoenix Financial Ltd. | 54,504,019 | 0 | 0 | 0 | For |
| MENORA MIVTACHIM HOLDINGS LTD. | 53,937,202 | 0 | 0 | 0 | For |
| Vanguard | 43,950,428 | 0 | 0 | 0 | For |
| Clal Insurance Enterprises Holdings Ltd | 37,718,089 | 0 | 0 | 0 | For |
| Capital Group | 16,685,206 | 0 | 0 | 0 | For |
| State Street | 15,630,512 | 58,957 | 0 | 0 | For |
| Altshuler Shaham Ltd | 0 | 11,463,884 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 10,605,632 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 10,209,344 | 0 | 0 | 0 | For |
| Janus Henderson | 9,449,845 | 0 | 0 | 0 | For |
| Charles Schwab | 9,035,840 | 0 | 0 | 0 | For |
| Y.D. More Investments Ltd | 0 | 8,426,222 | 0 | 0 | Against |
| Invesco | 7,307,227 | 0 | 0 | 0 | For |
| Northern Trust | 7,047,132 | 0 | 0 | 0 | For |
| GLENVIEW CAPITAL MANAGEMENT, LLC | 6,148,015 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Wellington | 5,658,324 | 0 | 0 | 0 | For |
| Legal & General Investment Management Ltd | 63,840 | 4,990,570 | 0 | 0 | Against |
| ION Fund Management Ltd | 3,883,183 | 0 | 0 | 0 | For |
| AustralianSuper Pty Ltd | 0 | 3,793,078 | 0 | 0 | Against |
| Alyeska Investment Group, L.P. | 3,773,343 | 0 | 0 | 0 | For |
| Victory Capital | 3,640,789 | 0 | 0 | 0 | For |
Showing the 25 largest of 615 asset managers. See all 615 in the interactive database.
Meeting held 2026-05-28.
Combines 5 wordings of this item as funds reported it.
72% Majority: yes · of votes cast
Teva Pharmaceutical Industries Limited’s own tally for this item (“Elect Director: Dr. Sol J. Barer”): 627,816,662 for, 245,921,571 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,164,426,972 outstanding shares: 53.9% for, 21% against (75% of the company cast a for/against vote).
The 109 asset managers below cast 99% of the shares they voted on this item FOR (142,464,972 for, 2,045,492 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 31,361,106 | 0 | 0 | 0 | For |
| Vanguard | 31,267,716 | 0 | 0 | 0 | For |
| BlackRock | 27,277,644 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Capital Group | 5,011,035 | 0 | 0 | 0 | For |
| Charles Schwab | 4,414,989 | 0 | 0 | 0 | For |
| TIAA | 2,550,548 | 0 | 0 | 0 | For |
| Jackson National | 2,511,684 | 16,909 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 2,446,446 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,353,527 | 0 | 0 | 0 | For |
| Lord Abbett | 2,232,424 | 0 | 0 | 0 | For |
| Hartford | 2,050,890 | 0 | 0 | 0 | For |
| State Street | 2,047,360 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,036,647 | 0 | 0 | 0 | For |
| Invesco | 1,876,080 | 0 | 0 | 0 | For |
| Victory Capital | 1,767,838 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 1,448,890 | 0 | 0 | 0 | For |
| SOUND SHORE FUND INC | 1,269,505 | 0 | 0 | 0 | For |
| First Trust | 1,160,521 | 0 | 0 | 0 | For |
| Prudential/PGIM | 996,900 | 0 | 0 | 0 | For |
| Allspring | 907,121 | 0 | 0 | 0 | For |
| Dimensional | 0 | 892,174 | 0 | 0 | Against |
| DWS | 615,337 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 574,218 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 0 | 525,000 | 0 | 0 | Against |
Showing the 25 largest of 109 asset managers. See all 109 in the interactive database.
Meeting held 2026-05-28.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Teva Pharmaceutical Industries Limited’s own tally for this item (“(3) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd.”): 880,542,242 for, 36,085,507 against, per its Form 8-K filed 2026-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 1,164,426,972 outstanding shares: 76% for, 3% against (79% of the company cast a for/against vote).
The 107 asset managers below cast 99.4% of the shares they voted on this item FOR (142,762,092 for, 809,305 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 31,361,106 | 0 | 0 | 0 | For |
| Vanguard | 31,267,716 | 0 | 0 | 0 | For |
| BlackRock | 27,277,644 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 5,843,812 | 0 | 0 | 0 | For |
| Capital Group | 5,011,035 | 0 | 0 | 0 | For |
| Charles Schwab | 4,414,989 | 0 | 0 | 0 | For |
| TIAA | 2,550,548 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 2,446,446 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,353,527 | 0 | 0 | 0 | For |
| Jackson National | 2,333,740 | 0 | 0 | 0 | For |
| Lord Abbett | 2,232,424 | 0 | 0 | 0 | For |
| Hartford | 2,049,659 | 1,231 | 0 | 0 | For |
| State Street | 2,047,360 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,036,647 | 0 | 0 | 0 | For |
| Invesco | 1,876,080 | 0 | 0 | 0 | For |
| Victory Capital | 1,767,838 | 0 | 0 | 0 | For |
| VanEck ETF Trust | 1,448,890 | 0 | 0 | 0 | For |
| SOUND SHORE FUND INC | 1,269,505 | 0 | 0 | 0 | For |
| First Trust | 1,160,521 | 0 | 0 | 0 | For |
| Prudential/PGIM | 996,900 | 0 | 0 | 0 | For |
| Allspring | 907,121 | 0 | 0 | 0 | For |
| Dimensional | 892,174 | 0 | 0 | 0 | For |
| DWS | 615,337 | 0 | 0 | 0 | For |
| MARSICO INVESTMENT FUND | 574,218 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 0 | 525,000 | 0 | 0 | Against |
Showing the 25 largest of 107 asset managers. See all 107 in the interactive database.
Meeting held 2026-05-28.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (449,778 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 0 | 0 | 0 | 0 | Not Voted |
| Dorsey Wright & Associates | 240,674 | 0 | 0 | 0 | For |
| Empower | 209,104 | 0 | 0 | 0 | For |
Meeting held 2026-05-28.
100% fund support · no official result
The 3 asset managers below cast 100% of the shares they voted on this item FOR (489,289 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Tidal Trust IV | 216,116 | 0 | 0 | 0 | For |
| Jackson National | 194,853 | 0 | 0 | 0 | For |
| John Hancock | 78,320 | 0 | 0 | 0 | For |
Reported under meeting date 2026-04-06; no official results on file for that date.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (3,333,349 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SCHRODER INVESTMENT MANAGEMENT GROUP | 3,329,114 | 0 | 0 | 0 | For |
| Robertson Stephens Wealth Management, LLC | 4,235 | 0 | 0 | 0 | For |
Ranked by the number of Teva Pharmaceutical Industries Limited shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 1,164,426,972 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 6.03% |
| 2 | Fidelity | 5.55% |
| 3 | Migdal Insurance & Financial Holdings Ltd. | 5.21% |
| 4 | Phoenix Financial Ltd. | 4.68% |
| 5 | MENORA MIVTACHIM HOLDINGS LTD. | 4.63% |
| 6 | Vanguard | 3.77% |
| 7 | Clal Insurance Enterprises Holdings Ltd | 3.24% |
| 8 | Capital Group | 1.43% |
| 9 | State Street | 1.35% |
| 10 | Altshuler Shaham Ltd | 0.98% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Harel Insurance Investments & Financial Services Ltd | 6.21% | 13G |
| BlackRock | 5.59% | 13F |
| Migdal Insurance & Financial Holdings Ltd | 5.30% | 13G |
| FMR (Fidelity) | 2.85% | 13F |
| State Street | 1.53% | 13F |
| Geode Capital | 0.91% | 13F |
| Morgan Stanley | 0.73% | 13F |
| Northern Trust | 0.66% | 13F |
| Wellington Management | 0.62% | 13F |
| JPMorgan Chase | 0.58% | 13F |
Percentages above are of 1,164,426,972 shares outstanding, as reported by Teva Pharmaceutical Industries Limited on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Teva Pharmaceutical Industries Limited’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Teva Pharmaceutical Industries Limited's shareholder meeting held 2026-05-28, in the 2025-2026 proxy season, 623 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,851 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION FOR TEVA'S NAMED EXECUTIVE… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Teva Pharmaceutical Industries Limited's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-28.
Teva Pharmaceutical Industries Limited proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).